Reach Us +44-1235-425476
Effect Of Multiple Peak Phenomena On Bioequivalence Results | 7844
ISSN : 2153-2435

Pharmaceutica Analytica Acta
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Effect of multiple peak phenomena on Bioequivalence results

2nd World Congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit-2011 and International Conference on Pharmaceutics & Novel Drug Delivery Systems

Sima Sadrai, Maryam Aryapoor, Hoda Lavasani

ScientificTracks Abstracts: PAA

DOI: 10.4172/2153-2435.10000S4

Many drugs when given orally demonstrate multiple peak phenomena in their concentration ? time profi les and the eff ects of this phenomenon on the results is considered in a cetirizine bioequivalence study. Bioequivalence of test tablet with reference tablet were compared in 22 healthy volunteers who received two 10mg tablets of cetirizine in a randomized blind cross over design. Blood samples were collected at 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 30 hours.RP-HPLC system consisted of a C 18 Nucleosil column 100?4 mm and mobile phase: buff er KH 2 PO 4 (PH=3),methanol and acetonitrile (53:40:7), fl ow rate: 1.4ml/min, oxazepam as internal standard and UV detection at 235nm was performed. Th e pharmacokinetic parameters mean?S.D of test tablet(Cetirizine): AUC (0-T) (2295.32?711.87)ng/ml*hr, AUC (0-∞) (3343.68?2402.76) ng/ml*hr, C max1 (288.00?114.71) ng/ml, C max2 (190.56?71.93) ng/ml, T max1 (0.76?0.33)hr and T max2 (3.84?2.05)hr. Th e pharmacokinetic parameters mean?S.D of reference tablet (Zyrtec): AUC (0-T) (2846.16?1156.32) ng/ml*hr, AUC (0-∞) (3693.68?2215.64) ng/ml*hr, C max1 (332.33?151.41) ng/ml, C max2 (299.52?113.01) ng/ml, T max1 (0.93?0.39)hr and T max2 (3.57?1.96)hr. Th e 90% confi dence interval are as follows: AUC (0-T) :67.9-104.1%, AUC (0-∞) :67.4- 118.2%, C max1 :66.5-110.7%, C max2 :69.7-110.0%, T max1 :63.0-99.5%, T max2 :84.5-130.5%. Th erefore the two products were not bioequivalent (out of acceptable 0.8-1.25% range ). E.g. three methods for evaluation of AUC (0-∞) were applied. Method A: fi nal k e aft er last peak, method B: mean k e and method C: k e calculated from fi nal 4 or 5 points concentration ? time curve. T-test between method A and B, A and C, B and C have demonstrated meaningful diff erence (p<0.005) between method A with B(0.017) and B with C(p<0.004). Multiple peak phenomena should be considered in bioequivalence studies and more details will be discussed.
Dr Sima Sadrai has completed her Ph.D from Tehran University of Medical Sciences 1995 about population pharmacokinetics of theophylline and postdoctoral studies from Uppsala University School of Pharmacy by Professor Mats Karlsson. She is associate professor in Tehran University of Medical Sciences. She has twenty two years teaching experience with special interest in pharmacokinetics modeling. She has published more than 20 papers and review in reputed journals.